European patent granted for CLTX technology used in CHM 1101
Filed with ASX · · 2 pages · English
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Partnership with OncoBay Clinical to advance CHM 1101
- Preliminary Final Report
- Chimeric Appoints Jennifer Chow as CEO & MD
- IND clearance received from US FDA for CHM 1101
- Chimeric licenses novel solid tumor CAR T therapy from Penn
Later from Chimeric Therapeutics
- First milestone on path to CDH17 CAR t clinical trial
- CLTX CAR t presents positive initial phase 1 clinical data
- CLTX CAR T data shows regional control of tumour recurrence
- Transformative Portfolio Expansion Presentation
- Chimeric receives US patent covering CLTX CAR technology
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics